Following the listing, the stock surged even further and touched an early high of Rs 1,242.75 on the BSE, while on the National Stock Exchange, it hit a high of Rs 1,244 in early trade.
The company's initial public offer was a major hit with investors and the firm had raised over Rs 411 crore through its IPO.
The quota reserved for qualified institutional buyers (QIBs) was oversubscribed 94.03 times and that of non institutional investors 393.10 times. Retail investors category was oversubscribed 11.6 times.
The company is the leading domestic enzyme firm engaged in research, development, manufacturing and marketing of over 400 proprietary products developed from 60 indigenous enzymes.